Bill Commons

NY A 5029

in committee

Relates to the substitution of brand name epinephrine auto-injectors with alternate epinephrine auto-injectors

New York · 2025-2026 Regular Session · lower

Quick answers

Did NY A 5029 pass?

Not yet. NY A 5029 is in committee as of 2026-01-07 and has not come to a final vote. Latest recorded action (2026-01-07): REFERRED TO HIGHER EDUCATION

What is NY A 5029 about?

Relates to the substitution of brand name epinephrine auto-injectors with alternate epinephrine auto-injectors in certain cases.

Who sponsors NY A 5029?

Jonathan Jacobson is the primary sponsor of NY A 5029.

Description

Relates to the substitution of brand name epinephrine auto-injectors with alternate epinephrine auto-injectors in certain cases.

Introduced
—
Latest action
2026-01-07 — REFERRED TO HIGHER EDUCATION
Bill type
bill
Last updated
—

Sponsors

  • Jonathan Jacobsonprimary

Committees

Not provided by source.

Action timeline

  1. 2025-02-11

    REFERRED TO HIGHER EDUCATION

    referral-committee

  2. 2026-01-07

    REFERRED TO HIGHER EDUCATION

    referral-committee

Versions

Documents

Votes

Not provided by source.

Related bills

  • Prior session: A 7219not in this corpus
  • Prior session: A 1181not in this corpus
  • Prior session: A 3981not in this corpus
  • Prior session: A 6988not in this corpus
  • Companion bill: S 1795

Official source

Attribution

Data from openstates_bulk_csv, retrieved 2026-07-24T05:28:30.722574Z

Inspect retained evidence for changes recorded after evidence tracking began:

Session-wide evidence can include changes to other bills:

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NY&identifier=A 5029. See the API docs or the MCP server for AI assistants.

Known limitations

  • Sponsor party and chamber affiliation are not yet captured by this API.
  • Committee referrals are not yet captured.

See the methodology page for data sources and limitations.